Discovery of Novel Tricyclic Full Agonists for the G-Protein-Coupled Niacin Receptor 109A with Minimized Flushing in Rats

Hong C. Shen(Roche (China)), Steven L. Colletti(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ning Ren(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ester Carballo‐Jane(Merck & Co., Inc., Rahway, NJ, USA (United States)), James R. Tata(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tsuei-Ju Wu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrew K.P. Taggart(Merck & Co., Inc., Rahway, NJ, USA (United States)), Qing Chen(Queensland University of Technology), M. Gerard Waters(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tom G. Holt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mihajlo L. Krsmanovic(Merck & Co., Inc., Rahway, NJ, USA (United States)), Milton L. Hammond(Merck & Co., Inc., Rahway, NJ, USA (United States)), Qiaolin Deng(Karolinska Institutet), Kang Cheng(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kenneth K. Wu(National Health Research Institutes), Michael S. Wolff(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tian‐Quan Cai(Merck & Co., Inc., Rahway, NJ, USA (United States)), Larissa Wilsie(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xinchun Tong(Merck & Co., Inc., Rahway, NJ, USA (United States)), Fa‐Xiang Ding(MACOM (United States))
Journal of Medicinal Chemistry
March 23, 2009
Cited by 80


Related Papers